Back to Explorer

Intravascular Administration Sets Premarket Notification Submissions [510(k)]: Guidance for Industry and FDA Staff

FinalCenter for Devices and Radiological Health07/11/2008

Description

FDA has developed thisguidance documentto assist industry in preparing premarket notification (510(k)s) submissions for intravascular (IV) administration sets and accessories. This revision of the document issued in 2005 updates the FDA-recognized standards and clarifies our recommendations for microbial ingress testing. IV administration sets and accessories include:

Scope & Applicability

Product Classes

4
Intravascular Administration Sets

Subject of the guidance document for premarket notification submissions.; Subject of the premarket notification guidance

Blood Administration Set

device used to administer and filter blood components

Class II

The devices that are the subject of this guidance are Class II non-spinal metallic bone screws and washers

Intravascular Administration Set

The primary device type covered by the guidance; device used to administer fluids from a container to a patient's vascular system

Stakeholders

1
manufacturer

Entity required to conduct postmarket surveillance; entity responsible for submitting postmarket surveillance plans; Entity holding the approved PMA, HDE, or cleared 510(k); The entity responsible for conducting postmarket surveillance and submitting reports.; Entity that can use the checklist as a reference for submissions.

Regulatory Context

Attributes

2
Substantial equivalence

Regulatory standard for 510(k) clearance; demonstration required for 510(k) submission; regulatory standard for 510(k) clearance; Comparison of subject device parameters to predicate 510(k) submission numbers.

Sterility assurance level (SAL) of 1 x 10⁻⁶

Required level for a sterile device

Identified Hazards

Hazards

4
Risks to Health

Identified risks that special controls must mitigate.

Unrestricted flow

Warning required for infusion pumps with no restricted flow feature

Adverse tissue reaction

Risk management information should identify hazardous situations such as adverse tissue reaction.

Infection

Risk to human health from failure to assure sterility

Related CFR Sections (4)

Related Warning Letters (10)

  • CGMP/QSR/Medical Devices/Adulterated

    Envoy Medical Inc.

    2025-12-09
  • CGMP/QSR/Medical Devices/Adulterated

    Hong Qiangxing Shenzhen Electronics Limited

    2025-11-25
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

    SeniorLife Technologies, Inc.

    2025-09-16
  • CGMP/QSR/Medical Devices/Adulterated

    Spectra Therapy, LLC

    2025-08-12
  • CGMP/QSR/Medical Devices/Adulterated

    Mectronic Medicale S.R.L.

    2025-08-05
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA)

    WHOOP, Inc.

    2025-07-15
  • CGMP/QSR/Medical Devices/Adulterated

    Aju Pharm Co., Ltd.

    2025-06-24
  • CGMP/QSR/Medical Devices/Adulterated

    Sedecal S.A.

    2025-05-27
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

    DRG Instruments GmbH

    2025-05-27
  • CGMP/QSR/Medical Devices/Adulterated

    NeuroSync, Inc.

    2025-05-20

See Also (8)